Fluoroquinolone-Associated Length of Stay Reduction in the Hospital Treatment of Community-Acquired Pneumonia

Infectious Diseases in Clinical Practice

Volumn 11, Issue 9, 2002, Pages 540-549

  Martin, Steven J ^a   Close, Sandy J ^a,b  

^a UNIVERSITY OF TOLEDO   (United States)

^b ST VINCENT MERCY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; AZTREONAM; CEFAZOLIN; CEFOTETAN; CEFTIZOXIME; CEFTRIAXONE; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; DRUG COST; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PNEUMONIA; RETROSPECTIVE STUDY;

EID: 0142124222     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000090384.89010.3c     Document Type: Article

References (12)

1. Barlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-382.
2. Centers for Disease Control and Prevention. Resistance of Streptococcus pneumoniae to fluoroquinolones-United States 1995-1999, MMWR 2001;50:800-804.
3. Urban C, Rahman N, Zhao X, et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis 2001;184:794-798.
4. Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-1729.
5. Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs; fluoroquinolone pharmacodynamics against Streptococcus pneumoniae, Diagn Microbiol Infect Dis 2000;38:151-157.
6. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000;109:378-385.
7. Gotfried MH, DeAbate CA, Fogarty C, et al. Comparison of 5-day, short course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin Ther 2001;23:97-107.
8. Chodosh S, Debate CA, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Resp Med 2000;94:18-27.
9. Gallagher KM, L'Italien G, Mauskopf J, et al. Abbreviated Length of Stay in Hospitalized Patients With Community-Acquired Pneumonia Treated With Gatifloxacin. Abstract 2246 at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1999.
10. Dresser LD, Miederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs. ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001;119:1439-1448.
11. Clark LC, Davis CW. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia. Am J Health-Sys Pharm 2000;57(suppl 3):S10-S13.
12. Marrie TJ, Lau CY, Wheller SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL study investigators community-acquired pneumonia intervention trial assessing levofloxacin. JAMA 2000;283:749-755.